Last updated: February 21, 2026
What is the Market Size for Inderal LA?
Inderal LA (propranolol long-acting) is a beta-blocker indicated for hypertension, angina, arrhythmias, and certain anxiety conditions. The drug represents a market segment primarily driven by patients with cardiovascular diseases.
Market Data (2022–2023)
- Global beta-blocker market valuation: USD 8.2 billion (Fortune Business Insights[1])
- Propranolol segment share: Approximate 20% of beta-blocker market
- Inderal LA sales (US, 2022): Estimated USD 600 million, accounting for 9% of the total beta-blocker market
- US market volume: Approximate 4.5 million prescriptions annually
- Growth rate of beta-blocker market: 3.6% CAGR (2022–2027)
Drivers
- Increasing prevalence of hypertension and cardiovascular conditions, especially among aging populations
- Elevated recognition of long-acting formulations for sustained symptom management
- Off-label use for performance anxiety
Challenges
- Price sensitivity among payers and patients
- Competition from generic formulations and other beta-blockers
- Patent expirations and market saturation
How Do Price Trends Compare Over Time?
Historical Pricing Data
Pricing Dynamics
- Brand-name pricing has decreased approximately 20% over seven years, aligning with patent expiration and generic market entry.
- Generic prices have remained relatively stable but are consistently lower than brand formulations, fueling substitution.
What Are Future Price Projections?
Assumptions
- Patent expiration for the brand-name Inderal LA: 2014
- Expected continued erosion of brand market share
- Increased generic acceptance
Projections (2023–2028)
| Year |
Estimated Average Price (USD per month) |
Market Share of Brand (%) |
Market Share of Generics (%) |
| 2023 |
180 |
15 |
85 |
| 2024 |
160 |
10 |
90 |
| 2025 |
140 |
8 |
92 |
| 2026 |
125 |
5 |
95 |
| 2027 |
120 |
2 |
98 |
| 2028 |
115 |
1 |
99 |
Impacts on Revenue
- Brand sales likely to decline to near zero by 2027–2028 unless a new formulation or indication is introduced.
- Overall market prices will stabilize around generic levels (~USD 50–70/month) unless a premium formulation emerges.
Competitive Landscape
Major Market Players
- Pfizer: Original patent holder, now offering generic propranolol LA
- Teva, Mylan, Sandoz: Key generic manufacturers
- Egis, Actavis: Other agents entering the market
Regulatory Considerations
- Generic approvals require bioequivalence studies
- US FDA approval can be granted based on abbreviated new drug applications (ANDAs)
Pricing Policy and Reimbursement
- Most US payers cover generic propranolol extensively
- Copayments are low for generics, influencing prescribing patterns
- Brand-name prescribing is more prevalent in cases of intolerance to generics or specific physician preference
Summary of Price Expectations
- Short-term (1–2 years): Prices for generics will likely remain stable, with slight fluctuations based on market competition.
- Mid-term (3–5 years): Prices may see slight reductions as manufacturing costs decrease or new generic entrants appear.
- Long-term (beyond 5 years): Market saturation will keep prices low, barring new patent protections or formulations.
Key Takeaways
- The proton of Inderal LA's market is shrinking due to patent expiration and generic competition.
- Prices have declined significantly over the past decade, with most new sales shifting towards generics.
- Future prices are expected to stabilize near generics' current price range, around USD 50–70/month.
- Revenue will decrease as brand share diminishes unless new indications or formulations are developed.
- Competitive dynamics favor generic manufacturers, pressuring pricing and market share.
FAQs
1. When did the patent for Inderal LA expire?
The patent expired in 2014, leading to a surge in generic versions.
2. Will the price of branded Inderal LA rebound?
Unlikely, without new formulations or indications, as market share shifts to generics.
3. How significant is off-label use for pricing?
Off-label prescriptions contribute to volume but do not significantly influence brand pricing.
4. Are biosimilars or alternatives emerging?
Biosimilars are not applicable; small-molecule drugs like propranolol primarily rely on generics.
5. What factors could alter the current price projections?
Regulatory changes, patent litigation, or new formulations could impact pricing and market share.
References
[1] Fortune Business Insights. (2022). Beta-Blockers Market Size, Share & Industry Analysis. Retrieved from https://www.fortunebusinessinsights.com
